ArticleJournal of Korean medical science2007
Downregulation of the RUNX3 gene by promoter hypermethylation and hemizygous deletion in breast cancer.
Article in Journal of Korean medical science, 2007. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 28 citations in OpenAlex.
- An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.Oncotarget · 2017Pooled it
- Clinicopathological significance and potential drug target of RUNX3 in breast cancer.Drug design, development and therapy · 2014Pooled it
- Association between RUNX3 promoter methylation and gastric cancer: a meta-analysis.BMC gastroenterology · 2011Pooled it
- Review
- Transcriptome changes induced byOncology letters · 2020Article
- The prognostic impact of hypermethylation for a panel of tumor suppressor genes and cell of origin subtype on diffuse large B-cell lymphoma.Molecular biology reports · 2019Article
- UnPAKing RUNX3 functions-Both sides of the coin.Small GTPases · 2019Review
- RUNX3 Epigenetic Inactivation Is Associated With Estrogen Receptor Positive Breast Cancer.The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society · 2018Article
- Loss of RUNX3 is significantly associated with advanced tumor grade and stage in endometrial cancers.Molecular medicine reports · 2018Article
- Quantitative Histone Mass Spectrometry Identifies Elevated Histone H3 Lysine 27 (Lys27) Trimethylation in Melanoma.Molecular & cellular proteomics : MCP · 2016Article
- The clinicopathological significance of RUNX3 hypermethylation and mRNA expression in human breast cancer, a meta-analysis.OncoTargets and therapy · 2016Article
- Expression of RUNX3 and β-catenin in the carcinogenesis of sporadic colorectal tubular adenoma.Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine · 2014Article
- RUNX3 is a prognostic marker and potential therapeutic target in human breast cancer.Journal of cancer research and clinical oncology · 2013Article
- Review
- Article
- DNA methylation of RUNX3 in papillary thyroid cancer.The Korean journal of internal medicine · 2012Article
- Tumor suppressor function of RUNX3 in breast cancer.Journal of cellular biochemistry · 2012Article
- EMP3 overexpression in primary breast carcinomas is not associated with epigenetic aberrations.Journal of Korean medical science · 2009Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The RUNX3 gene is regarded as a tumor suppressor gene in many human solid tumors, and its inactivation is believed to be related with solid tumor carcinogenesis. As little information is available about the role of the RUNX3 gene in breast cancer, we investigated the relationship between the RUNX3 gene and breast cancer. We performed reverse transcriptase-polymerases chain reaction (RT-PCR), methylation specific PCR, and bicolor fluorescent in situ hybridization analysis in an effort to reveal related mechanisms. Forty breast tissue samples and 13 cell lines were used in this study. Eighty-five percent of breast cancer tissues showed downregulated RUNX3 gene expression, whereas it was downregulated in only 25% of normal breast tissues by RT-PCR assay. Sixty-seven percent of breast cancer cell lines showed downregulated RUNX3 expression, but the RUNX3 gene was not expressed in two normal breast cell lines. Hypermethylation was observed in 53% of breast cancer tissues and 57% of breast cancer cell lines. Hemizygous deletion was observed in 43% of breast cancer cell lines. Hypermethylation and/or hemizygous deletion was observed in 5 of 7 breast cancer cell lines, and the four of these five examined showed no RUNX3 gene expression. We suggest that various mechanisms, including methylation and hemizygous deletion, could contribute to RUNX3 gene inactivation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.